KalVista Pharmaceuticals (KALV) Cash & Equivalents Growth (5y) (2021 - 2025)

KalVista Pharmaceuticals (KALV) Cash & Equivalents Growth (5y) (2021 - 2025) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn
7 Belite Bio 62.72 Bn 62.72 Bn -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn -
10 KalVista Pharmaceuticals 1.36 Bn 1.36 Bn 49.41 Mn

Historic Data

Download Data
DateValue
Jul 31, 2025 47.15%
Apr 30, 2025 52.82%
Oct 31, 2024 13.87%
Jul 31, 2024 1.13%
Apr 30, 2024 -0.14%
Jan 31, 2024 -16.37%
Oct 31, 2023 -13.79%
Jul 31, 2023 0.55%
Apr 30, 2023 1.95%
Jan 31, 2023 7.71%
Oct 31, 2022 6.53%
Jul 31, 2022 7.43%
Apr 30, 2022 -0.14%
Jan 31, 2022 6.35%
Oct 31, 2021 34.19%
Jul 31, 2021 25.34%